Home Cart Sign in  
Chemical Structure| 105628-72-6 Chemical Structure| 105628-72-6

Structure of Hydroxyfasudil
CAS No.: 105628-72-6

Chemical Structure| 105628-72-6

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Hydroxyfasudil, metabolite of Fasudil, is a potent Rho-kinase inhibitor and vasodilator.

Synonyms: HA-1100

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Hydroxyfasudil

CAS No. :105628-72-6
Formula : C14H17N3O3S
M.W : 307.37
SMILES Code : O=C1NC=CC2=C1C=CC=C2S(=O)(N3CCNCCC3)=O
Synonyms :
HA-1100
MDL No. :MFCD01752417
InChI Key :ZAVGJDAFCZAWSZ-UHFFFAOYSA-N
Pubchem ID :3064778

Safety of Hydroxyfasudil

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of Hydroxyfasudil

cytoskeleton

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
Bovine aortic endothelial cells (BAEC) 0.1 to 100 μmol/L 48 hours Hydroxyfasudil (0.1 to 100 μmol/L) did not affect eNOS promoter activity. Stroke. 2005 Oct;36(10):2251-7
Human saphenous vein endothelial cells (HSVEC) 10 μmol/L 18 hours Treatment with hydroxyfasudil increased eNOS mRNA expression to 156±20% (n=3, P<0.05). Stroke. 2005 Oct;36(10):2251-7
Human umbilical vein endothelial cells (HUVEC) 10 μmol/L 18 hours Treatment with hydroxyfasudil increased eNOS mRNA expression to 156±10% (n=3, P<0.05). Stroke. 2005 Oct;36(10):2251-7
Human aortic endothelial cells (HAEC) 0.1 to 100 μmol/L 18 hours Hydroxyfasudil increased eNOS mRNA and protein expression in a concentration-dependent manner, resulting in a 1.9- and 1.6-fold increase, respectively, at 10 μmol/L (P<0.05 for both). This correlated with a 1.5- and 2.3-fold increase in eNOS activity and NO production, respectively (P<0.05). Stroke. 2005 Oct;36(10):2251-7
Bovine aortic endothelial cells 10 μmol/L 24 hours Inhibited hyperglycemia-induced PAI-1 promoter activity Circulation. 2005 Jun 21;111(24):3261-8
Human saphenous vein endothelial cells (HSVECs) 10 μmol/L 24 hours Inhibited hyperglycemia-induced PAI-1 mRNA expression Circulation. 2005 Jun 21;111(24):3261-8
bovine aortic endothelial cells (BAECs) 30 μmol/L 60 minutes HF treatment led to a 4-fold increase in NO2 release, which was completely blocked by PI3-kinase inhibitor LY294002 or Akt inhibitor SH-5. Arterioscler Thromb Vasc Biol. 2004 Oct;24(10):1842-7
human saphenous endothelial cells 1 to 100 μmol/L 5 to 15 minutes HF produced a 1.8-fold increase in Akt serine-473 phosphorylation as early as 5 minutes, with a maximum 4.6-fold increase after 15 minutes. Arterioscler Thromb Vasc Biol. 2004 Oct;24(10):1842-7
Primary mouse neurons 10 µM 15 minutes Hydroxyfasudil significantly attenuated propofol-induced cleaved caspase-3 activation Anesthesiology. 2012 Feb;116(2):352-61
Guinea pig left atrium 10^-7 – 10^-4 M To evaluate the effect of Hydroxyfasudil on the contractile force of electrically paced guinea pig left atrium, showing no significant effect. Br J Pharmacol. 2001 Dec;134(8):1724-30
Guinea pig right atrium 10^-7 – 10^-4 M To evaluate the effect of Hydroxyfasudil on the spontaneous beating rate of guinea pig right atrium, showing no significant effect. Br J Pharmacol. 2001 Dec;134(8):1724-30
Mouse motor neuron cells (NSC34) 0.3, 3, 30 nM 27 hours To evaluate the protective effect of Hydroxyfasudil on SOD1G93A-induced motor neuron cell death. Results showed that at concentrations of 3-30 nM, Hydroxyfasudil reduced SOD1G93A-induced cell death in a concentration-dependent manner. Br J Pharmacol. 2013 Sep;170(2):341-51
Human PKD1 cystic cell line (OX161) 1–30 μM 7 days To test the efficacy of the ROCK inhibitor hydroxyfasudil in 3D cyst assays, results showed that hydroxyfasudil significantly reduced cyst area. JCI Insight. 2020 Aug 20;5(16):e135385
rat basilar artery 3 μmol/L 60 mins hypoxia ACh-induced endothelium-dependent relaxation was abolished during hypoxia and restored upon reoxygenation J Cereb Blood Flow Metab. 2007 May;27(5):998-1009
mouse aorta 3 μmol/L 90 mins (including 60 mins hypoxia) Partially restored endothelium-dependent ACh-induced relaxations during hypoxia, which was abolished by L-NAME, indicating eNOS mediation J Cereb Blood Flow Metab. 2007 May;27(5):998-1009

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice Wild-type or eNOS-deficient mice Intraperitoneal injection 1, 3, or 10 mg/kg/day(fasudil) Once daily for 2 days Fasudil increased cerebral blood flow to both ischemic and nonischemic brain areas, reduced cerebral infarct size by 33%, and improved neurologic deficit score by 37% (P<0.05). This correlated with inhibition of brain and vascular ROCK activity and increased eNOS expression and activity. The neuroprotective effects of fasudil were absent in eNOS-deficient mice. Stroke. 2005 Oct;36(10):2251-7
Mice Mesenteric ischemia-reperfusion injury model in wild-type and eNOS−/− mice Intraperitoneal 10 mg/kg(fasudil) Single dose 1 hour before ischemia Fasudil decreased leukocyte recruitment and adhesion to the mesenteric endothelium after I/R injury in wild-type but not in eNOS?/? mice. Arterioscler Thromb Vasc Biol. 2004 Oct;24(10):1842-7
Dogs Myocardial ischemia model induced by left anterior descending coronary artery stenosis Intravenous injection 0.1 and 0.3 mg/kg 30 minutes To evaluate the effect of Hydroxyfasudil on ST-segment depression in a canine myocardial ischemia model, showing dose-dependent suppression of ST-segment depression and increased blood flow in the LAD-perfused endomyocardium region. Br J Pharmacol. 2001 Dec;134(8):1724-30
Mice SOD1G93A mutant mice (ALS model) Administered via drinking water 30 and 100 mg/kg fasudil From 5 weeks of age until the experimental endpoint To evaluate the effect of Fasudil on disease progression and motor neuron loss in SOD1G93A mutant mice. Results showed that Fasudil delayed disease onset, prolonged survival time, and reduced motor neuron loss. Br J Pharmacol. 2013 Sep;170(2):341-51
Mouse Tetracycline-inducible kidney-specific Pkd1 mouse model (Pax8rtTA-TetO-Cre-Pkd1fl/fl) Intraperitoneal injection 10 mg/kg/day Once daily for 7 days To test the inhibitory effect of hydroxyfasudil on cyst growth in vivo, results showed that treated mice had significantly reduced kidney weights and cystic indices, and increased cilia length. JCI Insight. 2020 Aug 20;5(16):e135385
Mice (C57BL/6J and eNOS−/−) Distal middle cerebral artery occlusion (dMCAO) model Intraperitoneal or intravenous 10 mg/kg Single dose, 60 mins before or 5 mins after dMCAO In wild-type mice, hydroxyfasudil reduced the area of ischemic core and penumbra, but had no effect in eNOS?/? mice, indicating eNOS-dependent action J Cereb Blood Flow Metab. 2007 May;27(5):998-1009

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

3.25mL

0.65mL

0.33mL

16.27mL

3.25mL

1.63mL

32.53mL

6.51mL

3.25mL

References

 

Historical Records

Categories